[Disclosure] Celltrion Obtains South Korean MFDS Approval for Stoboclo and Osenvelt (068270)

Source Facts: Financial Supervisory Service Electronic Disclosure System (DART) / 2024-11-21

Disclosure Type: Major Management Matters Related to Investment Decisions

💡 3-Second Summary

Celltrion has officially obtained simultaneous marketing authorization from the South Korean Ministry of Food and Drug Safety (MFDS) for Stoboclo and Osenvelt (denosumab), biosimilars to Prolia and Xgeva, covering all indications approved for the reference products.

📊 1. [Key Disclosure Content & Major Financial Figures Summary]

• Target Products:
  • Stoboclo (CT-P41, Prolia biosimilar, Active ingredient: Denosumab)
  • Osenvelt (CT-P41, Xgeva biosimilar, Active ingredient: Denosumab)
• Approved Indications in the Disclosure:
  • Stoboclo:
    • Treatment of osteoporosis in postmenopausal women
    • Treatment to increase bone mass in men with osteoporosis
    • Treatment of glucocorticoid-induced osteoporosis
    • Treatment of bone loss in patients with non-metastatic prostate cancer receiving androgen deprivation therapy
    • Treatment of bone loss in women with breast cancer receiving adjuvant aromatase inhibitor therapy
  • Osenvelt:
    • Reduction of the risk of skeletal-related events in patients with multiple myeloma and bone metastases from solid tumors
    • Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity
• Key Schedule:
  • Application Date: December 29, 2023
  • Approval Date: November 21, 2024 (Fact confirmation date: November 21, 2024, verified via the MFDS approval notification)
  • Reviewing Authority: South Korean Ministry of Food and Drug Safety (MFDS)
• Specific Note: The approvals successfully cover all indications for which the reference products are approved, as stated in the disclosure.

📈 2. [Expert Perspective: What This Disclosure Means for Investors]

This filing represents a definitive regulatory milestone indicating that Celltrion has secured the legal marketing authorization required to commercialize Stoboclo and Osenvelt (CT-P41) in South Korea. It took approximately 11 months of regulatory review from the initial application date on December 29, 2023, to secure the final approvals.

From a financial perspective, this approval eliminates regulatory uncertainties regarding the domestic marketing authorization. However, this specific filing does not provide details on commercial terms, such as launch timelines, sales values, or the specific distribution structure. Consequently, investors should view this disclosure as the successful completion of the legal domestic approval pathway, without assuming immediate near-term revenue generation.

📝 Editor’s Comment (by K-STOCK Editor)

This MFDS approval serves as the direct administrative outcome of the “South Korean Marketing Authorization Application” originally filed on December 29, 2023. The essential fact is that final approval was granted for all five indications held by Prolia for osteoporosis and both indications held by Xgeva for skeletal-related event prevention.

Investors must note that this regulatory approval is strictly an administrative authorization and does not outline specific commercial parameters, product pricing, or distribution agreements. Therefore, evaluating the direct quantitative financial impact on the parent company based solely on this administrative disclosure is premature.

Consequently, the objective checkpoints for investors to monitor going forward are twofold: first, subsequent disclosures or corporate reports detailing the specific distribution and marketing entities assigned to commercialize the products; and second, the actual reporting of sales revenue for these two products in future periodic financial statements. Tracking these operational milestones represents the factual pathway to verifying the development’s eventual financial outcomes.

📢 Disclaimer & Source Information

Source: This content has been structured and newly drafted based on official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).

Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest solely with the investor.

Inquiries: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.